DIPROSONE 0.05% OINT 30G

Indications

Approved Uses

Relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (e.g., eczema/atopic dermatitis and psoriasis).

Dosage & Administration

Dosing by Condition

For corticosteroid-responsive dermatoses (including eczema/dermatitis and psoriasis): apply a thin layer to affected areas once or twice daily; reassess if not improving within ~2 weeks and avoid prolonged continuous use without clinician review.

Dose Adjustment Notes

Use the minimum effective amount for the shortest duration; apply once or twice daily and reduce frequency/stop as control is achieved; avoid use on large areas, under occlusion, or in skin folds unless directed due to increased systemic absorption; prolonged continuous use should generally not exceed 2-4 weeks without reassessment.

How to Take

For topical use only: wash and dry hands, apply a thin layer to the affected skin and rub in gently; avoid eyes, mouth, and mucous membranes and do not apply to broken/infected skin unless directed; wash hands after application (unless treating hands); do not use occlusive dressings/bandages unless prescribed.

Side Effects

Side Effect Frequency

Common: local burning/stinging, pruritus, irritation, dryness; Uncommon/Rare: folliculitis, acneiform eruptions, hypopigmentation, hypertrichosis, allergic contact dermatitis, perioral dermatitis, secondary infection, maceration, miliaria; Skin atrophy/striae and HPA-axis suppression are uncommon overall but risk increases with prolonged use, occlusion, large areas, and use on thin skin/children.

Safety & Warnings

Contraindications

Hypersensitivity to betamethasone dipropionate/excipients; untreated cutaneous viral infections (e.g., herpes simplex, varicella/vaccinia); untreated fungal or bacterial skin infections; rosacea; acne vulgaris; perioral dermatitis; pruritus ani/genital pruritus; not for ophthalmic use (avoid ocular application).

Drug Interactions

Drug Interactions

Clinically significant interactions are uncommon, but additive systemic corticosteroid effects can occur with other corticosteroids; strong CYP3A4 inhibitors (e.g., ritonavir/cobicistat, itraconazole) may increase systemic steroid effects if absorption is significant (large area, prolonged use, occlusion).

Interaction Severity

MODERATE: Strong CYP3A4 inhibitors (e.g., ritonavir/cobicistat, itraconazole) may increase systemic corticosteroid effects if significant percutaneous absorption occurs (large area, prolonged use, occlusion, pediatrics). MINOR: Concomitant use with other corticosteroids (topical/systemic) can add to total steroid burden.

Special Populations

Pregnancy

Caution

Breastfeeding

Caution

Storage & Patient Advice

Stopping the Medicine

Do not stop abruptly after prolonged use or use on large areas/under occlusion; taper by reducing frequency/potency to avoid rebound dermatitis and potential adrenal suppression.

Overdose

Excessive/prolonged topical use can cause HPA-axis suppression and hypercortisolism (Cushingoid features), hyperglycemia/glucosuria; manage by gradual withdrawal, supportive care, and monitoring adrenal function; accidental ingestion warrants medical assessment and symptomatic management.

Product Information

Available Dosage Forms

Ointment

Generic Availability

Yes

Skin Condition

Eczema, Psoriasis, Contact Dermatitis, Atopic Dermatitis

Steroid Potency

Potent.

Reviewed by Al Mujtama Pharmacy Medical Review Team. Last reviewed 10-06-2026